REGENXBIO Inc. (RGNX)

NMS – Real vaqt narxi. Valyuta: USD

10.91

+0.26 (2.44%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

10.87

-0.04 (-0.37%)

Bozordan keyin: Aug 12, 2026, 7:10 PM EDT

11.08.2026

Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)

Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months.

07.08.2026

REGENXBIO Q2 Earnings Call Highlights

REGENXBIO NASDAQ: RGNX reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic retinopathy study under its AbbVie collaboration.

06.08.2026

REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript

06.08.2026

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Regenxbio (RGNX) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $1.38 per share a year ago.

06.08.2026

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ®**, expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Reaffirmed path forward for RGX-121 for Hunter syndrome with FDA during productive July Type A meeting; resubmission on track for Q3 2026 Over $200 million new capital in July 2026 extends cash runway into Q4 2027 Pro forma ending Q2 2026 cash, cash equivalents and marketable securities in excess of $310 million Webcast today at 8:00 a.m. ET ROCKVILLE, Md.

03.08.2026

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
RGNX	Barclays	Equal Weight	undefined >> $12	August 7th 2026

Press-relizlar

06.08.2026

REGENXBIO Inc. (RGNX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

REGENXBIO Inc. (RGNX)